RXST
RxSight, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$6.38
−2.52%Aug 5, 2026, 23:11 UTC
RxSight, Inc. reported a second-quarter loss of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.21, and compared to a loss of $0.08 per share a year ago.
Jul 26, 2026, 20:00 UTC
RxSight granted inducement stock options and restricted stock units to its new President and CEO Aziz Mottiwala in connection with his commencement of employment.
Source:Jul 15, 2026, 20:15 UTC
RxSight announced the appointment of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz as Chief Medical Officer, effective July 20, 2026.
Source:Jul 11, 2026, 02:02 UTC
RxSight announced a strategic collaboration agreement with Alcon.
Source:Jul 6, 2026, 20:15 UTC
Alcon and RxSight announced a non-exclusive license agreement to collaborate on the development and commercialization of novel post-operative light adjustable PCIOL technologies.
Source: